Intelligent Bio Solutions Inc. announced the initiation of clinical studies to support a new FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, specifically targeting the detection of the opiate codeine. The clinical studies are designed to support FDA clearance and a planned commercial launch in the U.S. drug screening market. Subject recruitment and screening have begun, with the first testing cohort scheduled to start on January 28, 2026. Full data analysis from the studies is anticipated by the end of March 2026. The results from these studies will be incorporated into the company's FDA 510(k) submission package and have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9643633-en) on January 28, 2026, and is solely responsible for the information contained therein.